MedinCell S.A.

MEDCL

FR0004065605

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.

Sector

Pharmaceuticals

Calendar

25/06/2024 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for MedinCell S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.84 EUR

Average target price

17.15 EUR

Spread / Average Target

+15.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MEDINCELL S.A.	+106.11%	459M
ELI LILLY AND COMPANY	+32.95%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.97%	358B
MERCK & CO., INC.	+18.83%	328B
ABBVIE INC.	+3.54%	283B
ASTRAZENECA PLC	+15.70%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+6.70%	165B

Other Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:35:03 07/05/2024 BST			5-day change	1st Jan Change
14.84 ^EUR	+1.50%		+3.34%	+106.11%

05-08	CAC40: remains in green in a neglected market	CF
05-08	Medincell: positive results in schizophrenia	CF

CAC40: remains in green in a neglected market	05-08	CF
Medincell: positive results in schizophrenia	05-08	CF
Medincell Listing Temporarily Suspended on Euronext Paris	05-08	MT
Teva and Medincell's schizophrenia drug meets main goal of late-stage study	05-08	RE
Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-?749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	05-08	CI
CAC40: in green, builds on previous day's momentum	05-08	CF
Medincell: listing suspended pending a press release	05-08	CF
Medincell: share price rises following agreement with AbbVie	04-17	CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics	04-16	DJ
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies	04-16	CI
Medincell: Unitaid grant to combat malaria	04-09	CF
Medincell Receives $6 Million Extension Grant from Unitaid for Malaria Drug Trial	04-09	MT
Medincell S.A. Reaches Commercial Stage with the Market Launch by Teva of Uzedy? for the Treatment of Schizophrenia	03-15	CI
MedinCell: new Chairman of the Supervisory Board	03-14	CF
Medincell S.A. Appoints Philippe Guy as Chairman of Supervisory Board	03-13	CI
MedinCell: departure of Chairman of the Supervisory Board	02-19	CF
Biopharmaceutical Company MedinCell Chairman Exits	02-19	MT
MedinCell Announces Chairman Changes	02-19	CI
Teva Pharmaceutical Industries Ltd. Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable	01-09	CI
MedinCell: share price continues to rise, Jefferies to buy	01-05	CF
MedinCell: first-half net loss reduced	12-20	CF
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2023	12-19	CI
MedinCell: collaboration between Teva and Royalty Pharma	11-13	CF
MedinCell and European Investment Bank Sign an Amendment to the Loan Agreement	03/10/23	CI
Correction: MedinCell Completes Patient Recruitment for Late-stage Trial of Pain Relief Drug	31/08/23	MT